Review
doi: 10.1200/JCO.2010.33.3252.
Epub 2011 Apr 11.
Pathogenesis of non-Hodgkin's lymphoma
Affiliations
- PMID: 21483013
- DOI: 10.1200/JCO.2010.33.3252
Item in Clipboard
Review
Pathogenesis of non-Hodgkin's lymphoma
J Clin Oncol.
.
Abstract
The understanding of the molecular pathogenesis of non-Hodgkin's lymphomas (NHL) has significantly improved in recent years. Advances in molecular biology and genetics lead to the identification and characterization of several oncogenic pathways involved in lymphomagenesis. This knowledge will ultimately lead to improved diagnostic and therapeutic strategies for patients with NHL. This review summarizes current concepts of the molecular pathogenesis of the most common NHL subtypes, with a special emphasis on diffuse large B-cell lymphoma, the most common lymphoma subtype.
Similar articles
-
Characterization of IGH rearrangements in non-Hodgkin's B-cell lymphomas by fluorescence in situ hybridization.Anticancer Res. 2005 Sep-Oct;25(5):3179-82. Anticancer Res. 2005. PMID: 16101124
-
Molecular biology and genetics of lymphomas.Hematol Oncol Clin North Am. 2008 Oct;22(5):807-23, vii. doi: 10.1016/j.hoc.2008.07.004. Hematol Oncol Clin North Am. 2008. PMID: 18954738 Review.
-
Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma.Genes Chromosomes Cancer. 1998 May;22(1):72-8. Genes Chromosomes Cancer. 1998. PMID: 9591637 Review.
-
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas.Haematologica. 2008 Jul;93(7):1033-8. doi: 10.3324/haematol.12754. Epub 2008 May 19. Haematologica. 2008. PMID: 18492688
-
Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma.Semin Oncol. 1998 Aug;25(4):447-60. Semin Oncol. 1998. PMID: 9728595 Review.
Cited by
-
Aggressive B-cell lymphomas: how many categories do we need?Mod Pathol. 2013 Jan;26 Suppl 1(0 1):S42-56. doi: 10.1038/modpathol.2012.178. Epub 2012 Nov 16. Mod Pathol. 2013. PMID: 23154748 Free PMC article. Review.
-
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.Drug Des Devel Ther. 2018 Aug 21;12:2577-2590. doi: 10.2147/DDDT.S142406. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30174412 Free PMC article. Review.
-
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.Sci Rep. 2018 Oct 4;8(1):14814. doi: 10.1038/s41598-018-33230-3. Sci Rep. 2018. PMID: 30287880 Free PMC article.
-
Elevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin's Lymphoma in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation.Front Oncol. 2021 Oct 28;11:753712. doi: 10.3389/fonc.2021.753712. eCollection 2021. Front Oncol. 2021. PMID: 34778068 Free PMC article.
-
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15. Cancer Discov. 2017. PMID: 28619981 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
